While they are normally considered minor issues, from among the 10 most prevalent pathological conditions worldwide, 3 are dermatological. (1) For instance, in the United States, dermatological conditions account for 14 million medical visits and 850,000 admissions.(2)
The most frequent categories are fungal infections, skin and soft tissue infections (SSTIs) and acne. (1)These 3 groups encompass different common traits. On the one hand – and crucially – they might affect the quality of life not only of those suffering from the disease, but also that of their carer or carers, as occasionally the repercussions are not only symptomatic, sometimes requiring absenteeism from the workplace or school, which places a strain on a family’s everyday life.(3)
Furthermore, one of the main worries is the increased complication involved in securing sufficiently efficient treatment. In terms of medication for fungal infections or SSTIs, there is a situation that must be taken into account, and it is that the inappropriate use of antimicrobials has led to increased resistance to these products, deriving in a more serious public health issue.(4)
The main causative agents for SSTIs, which are S.pyogenes and especially S.aureus (5) already show resistance rates that can reach more than 70% in certain countries for certain molecules.(6) One of the most complex strains due to its consequences and difficulty to treat, the Methicillin-resistant Staphylococcus aureus (MRSA), causes that those infected have 64% more chances of running into complications than those infected with non-resistant strains (4).
A speedy diagnostic, together with the timely and sensible use of antimicrobial drugs optimises patients’ evolution and minimises the appearance of adverse pharmacological effects and the emergence of resistors.(7) We at Ferrer are committed to fostering the creation of global solutions and services to facilitate a quick detection and subsequent oral or topical treatment, in order to not only prevent transmission and facilitate the patient’s return to their educational or professional activities, but also to improve their quality of life, the quality of public and private assistance and to extend the lifespan of the treatments through rational use.
1 Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The Global Burdenof Skin Disease in 2010: AnAnalysisofthePrevalence and Impactof Skin Conditions. J InvestDermatol [Internet]. 2014 Jun [cited 2019 Feb 19];134(6):1527–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24166134
2 Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim- sulfamethoxazoleforuncomplicated skin infections. N Engl J Med 2015; 372:1093–103.)
3 Feaster T, et al. Topicaltherapiesforimpetigo. PediatrEmergCare. 2010;26(3):222–31.
4 WorldHealthOrganization. Antimicrobialresistance [Internet]. Factsheet. 2017 [cited 2017 Nov 7]. Availablefrom: http://www.who.int/mediacentre/factsheets/fs194/en/
5 Koning S, Van Der Sande R, Verhagen A, Van Suijlekom-smit L, Morris A, Butler C, et al. Interventionsforimpetigo( Review ). Cochrane Library. Cochrane DatabaseofSystemicReviews. John Wiley &Sons; 2012. Internet..Availablefrom: https://www.ncbi.nlm.nih.gov/pubmed/?term=Koning+2012+impetigo+metaanalysis.( consultado 29.07.2019)
6 WHO. Antimicrobialresistance [Internet]. Media Centre. WorldHealthOrganization; 2015 [Consultado julio 2019]. Available at: http://www.who.int/mediacentre/factsheets/fs194/en/
7 Doron S, Davidson LE. Antimicrobial Stewardship. Mayo Clin Proc 2011; 86(11):1113-1123.